Daniel F Hayes. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh: See more » Angiogenesis Inhibitors/adverse effectsAngiogenesis Inhibitors/economicsAngiogenesis Inhibitors/therapeutic useAntibodies, Monoclonal/adverse effectsAntibodies, Monoclonal/economicsAntibodies, Monoclonal/therapeutic useAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy Protocols/therapeutic useBevacizumabCombined Modality TherapyDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleDrug CostsEndpoint DeterminationHumansKaplan-Meier EstimateNeoplasms/drug therapyPatient SelectionRandomized Controlled Trials as Topic
Substances: See more » Angiogenesis InhibitorsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBevacizumab
Year: 2011 PMID: 21285431 DOI: 10.1001/jama.2011.57
Source DB: PubMed Journal: JAMA ISSN: 0098-7484 Impact factor: 56.272